Solanum nigrum Safety Assessment
Solanum nigrum should be discontinued at least 2 weeks before surgery due to potential effects on blood glucose control and possible antiplatelet activity, but there is insufficient evidence to recommend its routine clinical use given documented cases of acute interstitial nephritis and lack of standardized dosing or safety data for general medical practice.
Perioperative Management
The Society for Perioperative Assessment and Quality Improvement (SPAQI) does not specifically list Solanum nigrum in their 2021 consensus statement on dietary supplement management 1. However, based on the documented effects on glucose metabolism and potential antiplatelet activity demonstrated in research studies, it should be managed similarly to other supplements with hypoglycemic and anticoagulant properties.
Preoperative Recommendations:
- Hold for 2 weeks before surgery given:
- Demonstrated effects on insulin sensitivity and glucose metabolism 2
- Potential modulation of inflammatory pathways that could affect coagulation
- Lack of pharmacokinetic data on elimination half-life
Safety Concerns and Contraindications
Documented Adverse Effects:
Acute Interstitial Nephritis (AIN): The first documented case of biopsy-confirmed AIN following Solanum nigrum ingestion was reported in 2016, requiring corticosteroid therapy for resolution 3. This represents a serious, potentially reversible cause of acute kidney injury that clinicians must recognize.
Contraindications:
- Pre-existing kidney disease or dysfunction
- Concurrent use of nephrotoxic medications
- Patients on anticoagulants or antiplatelet agents
- Diabetic patients on insulin or oral hypoglycemics (risk of severe hypoglycemia)
Common Pitfalls:
- Assuming "natural" equals safe: Despite traditional use, documented nephrotoxicity exists
- Ignoring drug interactions: The plant affects glucose metabolism and may potentiate diabetic medications 2
- Lack of standardization: No FDA-approved formulations exist, making dosing unreliable
Dosing Considerations (Research Context Only)
Research studies have used varying preparations without standardization:
- Animal studies: 0.2-1.0 g/kg body weight of water extract 4
- Human traditional use: 1 g/L added to drinking water 2
- Critical caveat: These doses are from research settings and should not guide clinical practice due to lack of human safety trials and product standardization
Monitoring Requirements
If a patient reports using Solanum nigrum:
Laboratory monitoring should include:
- Baseline and serial creatinine/BUN (monitor for AIN)
- Urinalysis for proteinuria, hematuria, or white blood cell casts
- Fasting glucose and HbA1c in diabetic patients
- Liver function tests (AST, ALT, bilirubin) given hepatic metabolism
- Complete blood count if prolonged use
Clinical monitoring:
- Signs of acute kidney injury (decreased urine output, edema, fatigue)
- Hypoglycemic symptoms (tremor, confusion, diaphoresis)
- Bleeding or bruising
Evidence Quality Assessment
The available evidence presents a contradictory picture:
Protective effects demonstrated in animal models include hepatoprotection against CCl4-induced toxicity 5, 4 and improved glucose control in diabetic rats 2. Recent 2026 studies show potential anti-cancer 6 and anti-inflammatory mechanisms 7.
However, the single human case report of AIN 3 represents the highest quality evidence for clinical decision-making regarding safety in actual patients, not laboratory animals. This case report outweighs multiple animal studies when assessing real-world risk.
Clinical Recommendation
Do not recommend Solanum nigrum for any medical indication in routine clinical practice because:
- No FDA-approved formulations exist
- Documented human nephrotoxicity with unclear incidence
- Lack of standardized dosing or quality control
- Potential for serious drug interactions (antidiabetic agents, anticoagulants)
- All efficacy data derives from animal models or traditional use, not controlled human trials
If patients are already using it:
- Document use in medical record
- Initiate kidney function monitoring
- Assess for drug interactions, particularly with diabetic medications
- Strongly advise discontinuation 2 weeks before any surgical procedure
- Consider nephrology referral if any decline in renal function occurs
The risk-benefit ratio does not support clinical use given available safer alternatives for the conditions traditionally treated (diabetes, inflammation, liver disease) and the documented potential for irreversible organ damage.